InvestorsHub Logo
Followers 52
Posts 3430
Boards Moderated 0
Alias Born 05/10/2004

Re: None

Saturday, 02/25/2012 2:08:05 AM

Saturday, February 25, 2012 2:08:05 AM

Post# of 129051
I talked to the investor relations guy for a few minutes yesterday. He said he thought that our first target market would be South America. It didn't make any sense to me, until I did a search on Avon in Brazil. Turns out Avon sells more product in Brazil than in the US. Their economy also seems to be doing better than most in the world because, they have no dependence on oil. Most of their fuel is derived from sugarcane. Brazil is in the midst of a huge turnover ratio in their populus, from poverty to middle class. (the US seems to be going the opposite way) So it looks as though CBIS has a well thought out plan of attack. Go where the money is!!! LOL!

I snooped around a little more and found out Mexico decriminalized marijuanna in 2009, and with all the sun they get, our products might be a natural fit there.

Another target market may be Japan, in the near future. There was a lot of radiation released in that nuclear disaster. I would expect all manners of skin cancers to show up in the next few years. Hopefully CBIS can neutralize most of the problem..

There are just too many things that jump out at me, saying this is the one in a hundred stock that we all hunt for. Can you imagine the clout CBIS will have from the A&E segments if the biopsy reports are positive and can be added to the shows along with the visual documentation of the skin cancer cures? Joe Public will be demanding the FDA puts a rush on approval.
It might not even hurt to corner a few FDA guys on the TV shows.

The IR guy said that personally, he believed the share price will be above a buck, once the A&E shows are presented.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.